Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conflicting Data In Review Of New GnRH Risks

This article was originally published in The Pink Sheet Daily

Executive Summary

Writers of journal article say enough data exists to warrant more study of increased cardiovascular risks found in prostate cancer patients taking the drugs.

You may also be interested in...



FDAAA Safety Labeling Powers Are Invoked Selectively But Leave Drugmakers Little Room To Maneuver

FDA is being selective about when it invokes its authority under the Food and Drug Amendments Act of 2007 to require drug and biologic manufacturers to make safety-related label changes; however, when the agency does choose to act, industry has few options.

FDAAA Safety Labeling Powers Are Invoked Selectively But Leave Drugmakers Little Room To Maneuver

FDA is being selective about when it invokes its authority under the Food and Drug Amendments Act of 2007 to require drug and biologic manufacturers to make safety-related label changes; however, when the agency does choose to act, industry has few options.

FDA Clears Drugs With Post-Market Safety Questions Faster Than It Re-labels

FDA's "1early communication" program for alerting the public about potential drug safety issues produces a clean bill of health for products about 40 percent of the time, according to an analysis by "The Pink Sheet." And those positive decisions come much quicker than labeling changes the program has produced for drugs where genuine concerns have emerged

Related Content

Topics

UsernamePublicRestriction

Register

PS070695

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel